SEC Company Response from VERTEX PHARMACEUTICALS (VRTX) — Sep 20, 2007
VERTEX PHARMACEUTICALS INC / MA (VRTX) (CIK 0000875320)
Date: Sept. 20, 2007 · CIK: 0000875320 · Accession: 0001104659-07-070298
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-19319
Letter
VERTEX PHARMACEUTICALS INCORPORATED
130 WAVERLY STREET · CAMBRIDGE, MA 02139-4242
TEL. 617.444.6100 • FAX 617.444-6483
http://www.vrtx.com
September 20, 2007
Delivered by EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 6010
Washington, DC 20549
Attn: Tim Buchmiller, Senior Attorney
Re:
Vertex Pharmaceuticals Incorporated
Definitive Proxy Statement
Filed April 12, 2007
File No. 000-19319
Ladies and Gentlemen:
This letter relates to (i) comments from the staff of the Securities and Exchange Commission (the “Commission”) to Vertex Pharmaceuticals Incorporated (the “Company”) set forth in the staff’s letter to Dr. Joshua Boger, dated August 21, 2007 (the “Comment Letter”), regarding the Company’s Definitive Proxy Statement, which was filed with the Commission on April 12, 2007, and (ii) a conversation between a representative of the Company’s legal department and a representative of the staff of the Commission, which occurred on September 12, 2007. During such conversation, the staff of Commission (i) requested that the Company file this letter with the Commission on or before September 21, 2007 and (ii) confirmed that the Company’s proposed schedule for responding to the Comment Letter, as set forth in this letter, was acceptable to the Commission.
The Company hereby confirms:
1) That the Company has received the Comment Letter.
2) That the Company is in the process of drafting its response to the Comment Letter.
3) That the Company desires to discuss its response to the Comment Letter at the regularly scheduled October 17, 2007 meeting of the Company’s Management Development and Compensation Committee.
4) That the Company will file its response to the Comment Letter via EDGAR on or before October 23, 2007.
Please contact me at 617-444-6417 in the event that you have any questions or concerns with respect to this matter. In the event that I am not available, please contact my colleague, Valerie Andrews, at 617-444-6227.
Very truly yours,
/s/ Kenneth S. Boger
Show Raw Text
CORRESP 1 filename1.htm VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET · CAMBRIDGE, MA 02139-4242 TEL. 617.444.6100 • FAX 617.444-6483 http://www.vrtx.com September 20, 2007 Delivered by EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 6010 Washington, DC 20549 Attn: Tim Buchmiller, Senior Attorney Re: Vertex Pharmaceuticals Incorporated Definitive Proxy Statement Filed April 12, 2007 File No. 000-19319 Ladies and Gentlemen: This letter relates to (i) comments from the staff of the Securities and Exchange Commission (the “Commission”) to Vertex Pharmaceuticals Incorporated (the “Company”) set forth in the staff’s letter to Dr. Joshua Boger, dated August 21, 2007 (the “Comment Letter”), regarding the Company’s Definitive Proxy Statement, which was filed with the Commission on April 12, 2007, and (ii) a conversation between a representative of the Company’s legal department and a representative of the staff of the Commission, which occurred on September 12, 2007. During such conversation, the staff of Commission (i) requested that the Company file this letter with the Commission on or before September 21, 2007 and (ii) confirmed that the Company’s proposed schedule for responding to the Comment Letter, as set forth in this letter, was acceptable to the Commission. The Company hereby confirms: 1) That the Company has received the Comment Letter. 2) That the Company is in the process of drafting its response to the Comment Letter. 3) That the Company desires to discuss its response to the Comment Letter at the regularly scheduled October 17, 2007 meeting of the Company’s Management Development and Compensation Committee. 4) That the Company will file its response to the Comment Letter via EDGAR on or before October 23, 2007. Please contact me at 617-444-6417 in the event that you have any questions or concerns with respect to this matter. In the event that I am not available, please contact my colleague, Valerie Andrews, at 617-444-6227. Very truly yours, /s/ Kenneth S. Boger Kenneth S. Boger Senior Vice President and General Counsel 2